ID | Age (years) | Sex | Treatment | Side-effects | Mean PAP | WHO-FC | All-day oxygen | PHQ-9 score | GAD-7 score |
A | 60s | M | Oral | None | 38 | II | + | 11 | 6 |
B | 30s | M | Subcutaneous injection+oral | Subcu-taneous injection-site pain | 42 | II | – | 13 | 7 |
C | 40s | M | Oral | Fatigue | 45 | II | – | 10 | 10 |
D | 50s | F | Oral | Nausea, foot-pain, fatigue | 34 | II | – | 14 | 20 |
E | 20s | F | Intravenous +oral | Foot pain, jaw pain, Hot-flushes | 49 | II | + | 15 | 13 |
F | 20s | F | Oral | nausea | 66 | II | – | 12 | 2 |
Mean45.7 SD11.3 | Mean12.5 SD1.9 | Mean9.7 SD6.3 |
F, female; GAD-7, 7-item Generalised Anxiety Disorder questionnaire; M, male; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PHQ-9, 9-item Patient Health Questionnaire; WHO-FC, WHO-Functional Class.